Scientists develop first-of-its-kind antibody to block Epstein Barr virus
_Particles.jpg){kind=link}
Using mice with human antibody genes, scientists have developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the Epstein Barr virus (EBV) from binding to and entering human immune cells.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.